PIK3CA及GST-π在人骨肉瘤中的表达及其临床意义

Abstract
Figure/Table
References (20)
Related Citation (4)

Download: PDF (613 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective To detect the expression of phosphatidylinositol 3-kinase (PIK3CA) and glutathione-S transferase-π (GST-π) in osteosarcoma tissues and to explore its effect on the multidrug resistance of osteosarcoma. Methods Thirty-three cases of pathological tissue specimens of osteosarcoma from Renmin Hospital of Wuhan University from January 2009 to June 2017 were collected. The expression of PIK3CA and GST-π of 33 cases of osteosarcoma specimens was detected by immunohistochemistry (Envision method) and Western blot method. The differences between the chemotherapy-resistant group (7 cases) and the chemotherapy-effective group (26 cases) were compared. The results were analyzed combined with clinicopathological factors. Results The average optical density of PIK3CA in the chemotherapy-resistant group and chemotherapy-effective group was (11.089±2.147) and (6.938±2.065) respectively, and there was a significant difference between the two groups (P ＜ 0.05); the average optical density of GST-π in the chemotherapy-resistant group and chemotherapy-effective group was (15.871±2.678) and (7.693±2.443), and there was a significant difference between the two groups (P ＜ 0.05). The average optical density of PIK3CA and GST-π by Western blot method had significant differences between the two groups (P ＜ 0.05). The expression of PIK3CA and GST-π in osteosarcoma was correlated (r = 0.68, P ＜ 0.01). Conclusion PIK3CA and GST-π are over expressed in osteosarcoma chemotherapy-resistant group, and the expression of PIK3CA and GST-π is positively correlated with each other, which may be one of the mechanisms of drug resistance in osteosarcoma.

Key words： Osteosarcoma Phosphatidylinositol 3-kinase Glutathione-S transferase Multidrug resistance

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DING Wanjun1 HUANG Li2 ZENG Tao3 GE Wei1 ZHANG Yukun1 GUO Weichun4 YU Ling4

Cite this article:

DING Wanjun1 HUANG Li2 ZENG Tao3 GE Wei1 ZHANG Yukun1 GUO Weichun4 YU Ling4. Expression of PIK3CA and GST-π in human osteosarcoma and its clinical significance[J]. 中国医药导报, 2018, 15(16): 21-24.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I16/21

[1] Bousquet M，Noirot C，Accadbled F，et al. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations [J]. Ann Oncol，2016，27（4）：738-744.
[2] Jiang F，Shi Y，Li GJ，et al. A meta analysis of limb salvage versus amputation in the treatment of patients with EnnekingⅡ pathologic fracture osteosarcoma [J]. Indian J Cancer，2015，2（6）：21-24.
[3] Chen R，Wang G，Zheng Y，et al. Long non-coding RNAs in osteosarcoma [J]. Oncotarget，2017，8（12）：20462-20475.
[4] 杜敏东，易生辉，秦刚，等.新辅助化疗结合保肢手术治疗骨肉瘤26例[J].中国医药导报，2017，14（29）：7-10.
[5] Jabeen S，Holmboe L，Andersen AM，et al. Impact of genetic variants of RFC1，DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate [J]. Pharmacogenomics J，2015，15（5）：385-390.
[6] 邹翩，裴江鸿，石卫，等.基于GST-π的抗肿瘤药物研究进展[J].药学学报，2016，51（2）：241-247.
[7] Wang J，Wenjuan W，Cai H，et al. MACC1 facilitates chemoresistance and cancer stem cell like properties of colon cancer cells through the PI3K/AKT signaling pathway [J]. Mol Med Rep，2017，16（6）：8747-8754.
[8] He ML，Wu Y，Zhao JM，et al. PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population [J]. Asian Pac J Cancer Prev，2013，14（9）：5117-5122.
[9] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline（version1.1）[J]. Eur J Cancer，2009，45（2）：228-247.
[10] Kirtane AR，Kalscheuer SM，Panyam J. Exploiting nanotechnology to overcome tumor drug resistance：challenges and opportunities [J]. Adv Drug Deliv Rev，2013， 65（13/14）：1731-1747.
[11] Ebeed SA，Sadek NA，Zaher ER，et al. Role of MRP-1 and GST-Pi in MDR and their inhibition by indomethacin in AML [J]. Alexandria Journal of Medicine，2017，53（3）：251-259.
[12] 杨艳，杜云翔，张闯，等.p63、P-gp、GST-π及Topo-Ⅱ在食管鳞癌组织中的表达[J].东南大学学报，2016，35（6）：927-931.
[13] Di-Pietro G，Magno LA，Rios-Santos F. Glutathione S-transferases：an overview in cancer research [J]. Expert Opin Drug Metab Toxicol，2010，6（2）：153-170.
[14] 翟墨.新辅助化疗联合保肢手术治疗骨肉瘤的临床研究[J].中国现代医生，2016，54（1）：58-61.
[15] 沈志华，郭菁菁.黄芩苷对人骨肉瘤MG63细胞凋亡及MMPs表达的影响[J].中国药房，2016，27（4）：488-490.
[16] 张栋，孔德璇，和珍珍，等.PI3K/AKT信号转导通路与卵巢癌顺铂耐药相关性的研究[J].天津医药，2011，39（4）：361-363.
[17] Nakayama I，Shinozaki E，Matsushima T，et al. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients [J]. BMC Cancer，2017，17（1）：38.
[18] 蔡奋忠，林雄哲.胶质瘤PI3K/AKT/mTOR信号通路靶向治疗研究进展[J].中国现代医生，2016，54（30）：165-168.
[19] 贾成舒，王均伟，李慧，等.PI3K抑制剂与其他药物联用克服耐药性的研究进展[J].中国医药大学学报，2017， 48（5）：523-528.
[20] Gobin B，Huin MB，Lamoureux F，et al. BYL719，a new alpha-specific PI3K inhibitor：single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma [J]. Int J Cancer，2015，136（4）：784-796.